This study intends to apply for the establishment of research beds, establish a Chinese PVRL research cohort, and carry out a to achieve the following research objectives: The goal of this prospective observational study is to construct the diagnosis and treatment system for primary vitreoretinal lymphoma(PVRL). The study is to achieve the following research objectives: 1. To establish a comprehensive diagnostic criteria for PVRL with high diagnostic efficiency and strengthen the PVRL diagnostic system; 2. To establish a standardized treatment pathway for PVRL and evaluate the efficacy and safety of treatment; 3. To screen the prognosis evaluation indicators, and to establish the follow-up process and prognosis evaluation system of PVRL; 4. To explore the pathogenesis of PVRL, specific tumor markers and drug therapeutic targets.
Study Type
OBSERVATIONAL
Enrollment
100
Intravitreal injection of methotrexate:400ug/0.1mL,Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year) Systemic therapy: Induction period:(Zanubrutinib + Rituximab,ZR) (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGInterleukin-10/Interleukin-6(IL-10/IL-6)
aqueous fluid
Time frame: 1 year
Interleukin-10/Interleukin-6(IL-10/IL-6)
cerebrospinal
Time frame: 2.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.